NASDAQ:OCDX

Ortho Clinical Diagnostics Competitors

$21.17
-0.52 (-2.40 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.46
$21.69
50-Day Range
$18.06
$21.69
52-Week Range
$15.14
$21.82
Volume1.33 million shs
Average Volume1.59 million shs
Market Capitalization$4.71 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Ortho Clinical Diagnostics (NASDAQ:OCDX) Vs. BIO.B, NVCR, DGX, VTRS, BIO, and INCY

Should you be buying OCDX stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Ortho Clinical Diagnostics, including Bio-Rad Laboratories (BIO.B), NovoCure (NVCR), Quest Diagnostics (DGX), Viatris (VTRS), Bio-Rad Laboratories (BIO), and Incyte (INCY).

Ortho Clinical Diagnostics (NASDAQ:OCDX) and Bio-Rad Laboratories (NYSE:BIO.B) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for Ortho Clinical Diagnostics and Bio-Rad Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ortho Clinical Diagnostics011102.92
Bio-Rad Laboratories0000N/A

Ortho Clinical Diagnostics currently has a consensus target price of $24.5455, suggesting a potential upside of 15.94%. Given Ortho Clinical Diagnostics' higher possible upside, equities analysts clearly believe Ortho Clinical Diagnostics is more favorable than Bio-Rad Laboratories.

Institutional & Insider Ownership

0.1% of Bio-Rad Laboratories shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Ortho Clinical Diagnostics and Bio-Rad Laboratories' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A
Bio-Rad Laboratories$2.31 billion8.15$1.76 billionN/AN/A

Bio-Rad Laboratories has higher revenue and earnings than Ortho Clinical Diagnostics.

Profitability

This table compares Ortho Clinical Diagnostics and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ortho Clinical DiagnosticsN/AN/AN/A
Bio-Rad Laboratories147.91%3.77%2.74%

Summary

Bio-Rad Laboratories beats Ortho Clinical Diagnostics on 6 of the 8 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and Ortho Clinical Diagnostics (NASDAQ:OCDX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for NovoCure and Ortho Clinical Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
Ortho Clinical Diagnostics011102.92

NovoCure presently has a consensus target price of $195.7143, suggesting a potential upside of 7.53%. Ortho Clinical Diagnostics has a consensus target price of $24.5455, suggesting a potential upside of 15.94%. Given Ortho Clinical Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Ortho Clinical Diagnostics is more favorable than NovoCure.

Institutional and Insider Ownership

71.1% of NovoCure shares are held by institutional investors. 5.1% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares NovoCure and Ortho Clinical Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million53.58$-7,230,000.00($0.07)-2,600.14
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A

Ortho Clinical Diagnostics has lower revenue, but higher earnings than NovoCure.

Profitability

This table compares NovoCure and Ortho Clinical Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
Ortho Clinical DiagnosticsN/AN/AN/A

Summary

NovoCure beats Ortho Clinical Diagnostics on 6 of the 9 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and Ortho Clinical Diagnostics (NASDAQ:OCDX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Quest Diagnostics and Ortho Clinical Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics05702.58
Ortho Clinical Diagnostics011102.92

Quest Diagnostics presently has a consensus target price of $139.75, suggesting a potential downside of 1.22%. Ortho Clinical Diagnostics has a consensus target price of $24.5455, suggesting a potential upside of 15.94%. Given Ortho Clinical Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Ortho Clinical Diagnostics is more favorable than Quest Diagnostics.

Institutional and Insider Ownership

85.7% of Quest Diagnostics shares are held by institutional investors. 1.5% of Quest Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Quest Diagnostics and Ortho Clinical Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.39$858 million$6.5621.57
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A

Quest Diagnostics has higher revenue and earnings than Ortho Clinical Diagnostics.

Profitability

This table compares Quest Diagnostics and Ortho Clinical Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
Ortho Clinical DiagnosticsN/AN/AN/A

Summary

Quest Diagnostics beats Ortho Clinical Diagnostics on 6 of the 9 factors compared between the two stocks.

Viatris (NASDAQ:VTRS) and Ortho Clinical Diagnostics (NASDAQ:OCDX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Viatris and Ortho Clinical Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viatris18402.23
Ortho Clinical Diagnostics011102.92

Viatris presently has a consensus target price of $18.4444, suggesting a potential upside of 22.64%. Ortho Clinical Diagnostics has a consensus target price of $24.5455, suggesting a potential upside of 15.94%. Given Viatris' higher possible upside, equities research analysts clearly believe Viatris is more favorable than Ortho Clinical Diagnostics.

Earnings and Valuation

This table compares Viatris and Ortho Clinical Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViatrisN/AN/AN/AN/AN/A
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A

Profitability

This table compares Viatris and Ortho Clinical Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ViatrisN/AN/AN/A
Ortho Clinical DiagnosticsN/AN/AN/A

Summary

Ortho Clinical Diagnostics beats Viatris on 2 of the 3 factors compared between the two stocks.

Ortho Clinical Diagnostics (NASDAQ:OCDX) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Ortho Clinical Diagnostics and Bio-Rad Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ortho Clinical Diagnostics011102.92
Bio-Rad Laboratories00303.00

Ortho Clinical Diagnostics presently has a consensus price target of $24.5455, suggesting a potential upside of 15.94%. Bio-Rad Laboratories has a consensus price target of $700.00, suggesting a potential upside of 15.96%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Ortho Clinical Diagnostics.

Profitability

This table compares Ortho Clinical Diagnostics and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ortho Clinical DiagnosticsN/AN/AN/A
Bio-Rad Laboratories147.91%3.77%2.74%

Institutional and Insider Ownership

63.0% of Bio-Rad Laboratories shares are held by institutional investors. 27.5% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Ortho Clinical Diagnostics and Bio-Rad Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A
Bio-Rad Laboratories$2.31 billion7.77$1.76 billion$7.0685.50

Bio-Rad Laboratories has higher revenue and earnings than Ortho Clinical Diagnostics.

Summary

Bio-Rad Laboratories beats Ortho Clinical Diagnostics on 8 of the 9 factors compared between the two stocks.

Ortho Clinical Diagnostics (NASDAQ:OCDX) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Ortho Clinical Diagnostics and Incyte, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ortho Clinical Diagnostics011102.92
Incyte18802.41

Ortho Clinical Diagnostics presently has a consensus price target of $24.5455, suggesting a potential upside of 15.94%. Incyte has a consensus price target of $99.50, suggesting a potential upside of 22.25%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than Ortho Clinical Diagnostics.

Profitability

This table compares Ortho Clinical Diagnostics and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ortho Clinical DiagnosticsN/AN/AN/A
Incyte-13.62%-13.66%-9.98%

Institutional and Insider Ownership

91.4% of Incyte shares are held by institutional investors. 16.1% of Incyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Ortho Clinical Diagnostics and Incyte's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A
Incyte$2.16 billion8.29$446.91 million$2.2336.50

Incyte has higher revenue and earnings than Ortho Clinical Diagnostics.

Summary

Ortho Clinical Diagnostics beats Incyte on 5 of the 9 factors compared between the two stocks.


Ortho Clinical Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BIO.B
Bio-Rad Laboratories
0.7$631.85-0.0%$18.85 billion$2.31 billion5.41
NovoCure logo
NVCR
NovoCure
1.6$182.01-5.7%$18.82 billion$351.32 million958.00
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$141.48-1.8%$18.48 billion$7.73 billion17.49Analyst Upgrade
News Coverage
Viatris logo
VTRS
Viatris
1.5$15.04-6.4%$18.18 billionN/A0.00Earnings Announcement
High Trading Volume
Gap Up
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$603.65-0.7%$17.97 billion$2.31 billion5.17
Incyte logo
INCY
Incyte
1.6$81.39-1.7%$17.90 billion$2.16 billion-51.84Earnings Announcement
Catalent logo
CTLT
Catalent
1.7$104.80-2.6%$17.85 billion$3.09 billion66.75Earnings Announcement
Avantor logo
AVTR
Avantor
2.0$30.48-2.4%$17.74 billion$6.04 billion254.00
STERIS logo
STE
STERIS
2.1$207.64-1.9%$17.72 billion$3.03 billion42.12Upcoming Earnings
Cardinal Health logo
CAH
Cardinal Health
2.4$58.33-0.3%$17.13 billion$152.92 billion17.62Earnings Announcement
Dividend Increase
Analyst Downgrade
Gap Down
Exact Sciences logo
EXAS
Exact Sciences
2.0$98.84-5.7%$16.96 billion$876.29 million-44.72
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$332.88-2.9%$16.73 billion$2.62 billion55.48Insider Selling
Analyst Revision
Hologic logo
HOLX
Hologic
2.3$65.09-0.8%$16.68 billion$3.78 billion15.50
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07-0.0%$16.26 billion$3.17 billion60.43
PPD logo
PPD
PPD
1.7$46.12-0.0%$16.19 billion$4.03 billion307.47
Bio-Techne logo
TECH
Bio-Techne
1.8$408.23-3.6%$15.84 billion$738.69 million65.32Earnings Announcement
Dividend Announcement
Molina Healthcare logo
MOH
Molina Healthcare
1.5$268.74-0.3%$15.69 billion$16.83 billion20.15
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.24-2.0%$15.24 billion$3.07 billion-56.56Earnings Announcement
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$128.63-2.1%$15.12 billion$219.75 million-16.43
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$69.12-0.9%$15.08 billion$4.03 billion-300.52Earnings Announcement
Analyst Revision
Insulet logo
PODD
Insulet
1.6$226.75-3.3%$15.01 billion$738.20 million515.35Analyst Revision
10x Genomics logo
TXG
10x Genomics
2.0$134.84-8.5%$14.66 billion$245.89 million-99.88Earnings Announcement
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.39-1.8%$13.96 billion$1.70 billion17.48Insider Selling
Oak Street Health logo
OSH
Oak Street Health
1.7$56.76-2.4%$13.66 billionN/A0.00
DaVita logo
DVA
DaVita
1.7$127.98-0.9%$13.59 billion$11.39 billion19.19
Universal Health Services logo
UHS
Universal Health Services
1.8$157.05-1.2%$13.36 billion$11.38 billion15.40
Zai Lab logo
ZLAB
Zai Lab
1.6$149.45-5.8%$13.33 billion$12.98 million-49.32
argenx logo
ARGX
argenx
1.3$257.11-2.6%$13.19 billion$78.17 million-54.36Upcoming Earnings
Analyst Upgrade
News Coverage
AGL
agilon health
1.0$33.48-0.0%$12.86 billionN/A0.00Analyst Report
News Coverage
Grifols logo
GRFS
Grifols
1.3$18.60-2.0%$12.79 billion$5.71 billion16.61Earnings Announcement
Abiomed logo
ABMD
Abiomed
1.6$282.72-5.0%$12.79 billion$840.88 million62.14
GoodRx logo
GDRX
GoodRx
1.5$31.45-10.5%$12.33 billion$388.22 million0.00Upcoming Earnings
Analyst Report
Guardant Health logo
GH
Guardant Health
1.9$121.78-11.2%$12.31 billion$214.38 million-63.76Earnings Announcement
ICON Public logo
ICLR
ICON Public
2.0$225.39-1.5%$12.09 billion$2.81 billion37.57Analyst Report
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.20-1.6%$12.01 billion$2.32 billion59.67
Masimo logo
MASI
Masimo
1.8$216.88-3.4%$11.93 billion$937.84 million56.33
Novavax logo
NVAX
Novavax
1.6$160.50-9.7%$11.89 billion$18.66 million-30.75Gap Down
Henry Schein logo
HSIC
Henry Schein
1.6$82.97-2.8%$11.67 billion$9.99 billion20.44Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.25-1.5%$11.19 billion$16.89 billion-2.79Analyst Report
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.6$170.67-1.0%$11.06 billion$3.07 billion49.90Analyst Downgrade
QIAGEN logo
QGEN
QIAGEN
1.7$46.89-1.6%$10.69 billion$1.53 billion57.89
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.10-0.9%$10.02 billion$2.16 billion55.55Earnings Announcement
Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
2.1$27.53-2.0%$9.87 billion$8.60 billion-5.05
Repligen logo
RGEN
Repligen
1.9$175.13-7.2%$9.62 billion$270.24 million213.57Earnings Announcement
Analyst Revision
Penumbra logo
PEN
Penumbra
1.7$263.37-3.1%$9.61 billion$547.41 million-975.44Earnings Announcement
Canopy Growth logo
CGC
Canopy Growth
1.1$24.18-4.5%$9.26 billion$297.34 million-7.24
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.82-3.7%$9.23 billionN/A0.00News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$91.24-0.2%$8.63 billion$788.10 million98.11Earnings Announcement
Syneos Health logo
SYNH
Syneos Health
1.6$82.64-0.2%$8.62 billion$4.68 billion45.41
Encompass Health logo
EHC
Encompass Health
2.0$86.58-1.4%$8.62 billion$4.61 billion32.43Dividend Announcement
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.